Quote:

---

Participant satisfaction and qualitative data: “it might be painful, but it is better than pills”

---

Can develop resistance.

In Atlas trial - Grade 3+ laboratory abnormalities ranged between 18% to 28% depending on dosage and method of administration.
https://www.dovepress.com/cr_data/article_ful..._T0001.jpg

Side effects - Oral rilpivirine needs to be taken with a meal for optimal absorption and cannot be co-administered with proton-pump inhibitors.21 Frequently occurring side effects (SE) are headaches, insomnia, dizziness and nausea, increases in total and low-density lipoprotein cholesterol, rises in pancreatic amylase and derangement of transaminases

Of note, those on fixed-dose combination abacavir, lamivudine and dolutegravir were excluded and a reason for this is not given. Also excluded were individuals with a prior switch due to treatment failure (HIV-1 RNA≥400 copies/mL), those who have had over one-month break from ART and those with clinically significant comorbidities. This may limit generalizability outside of these groups.

As seen in FLAIR, there was some resistance emerging at failure in the LA therapy arm and further study on this is warranted.

In the licensing studies for rilpivirine, ECHO and THRIVE,12,13 and similarly in the STAR study,46 treatment-naïve adults with any of 39 NNRTI mutations at baseline were excluded
https://www.dovepress.com/evaluating-cabotegr...rticle-HIV